25/10/2007 - 13:20

TetraQ to market NeuroSolutions in Australasia

25/10/2007 - 13:20

Bookmark

Save articles for future reference.

Perth-based neurology research company NeuroDiscovery Ltd has invited Queensland-based TetraQ Pty Ltd to market the safety pharmacology services of subsidiary NeuroSolutions Ltd in Australasia, the company has announced.

Perth-based neurology research company NeuroDiscovery Ltd has invited Queensland-based TetraQ Pty Ltd to market the safety pharmacology services of subsidiary NeuroSolutions Ltd in Australasia, the company has announced.

 

 

The full text of a company announcement is pasted below

NeuroDiscovery Ltd (ASX: NDL) a neurology focused research and development company, has invited TetraQ Pty Ltd to market the safety pharmacology services of NeuroDiscovery's 100% subsidiary, NeuroSolutions Ltd in Australasia.

University of Queensland based TetraQ is the premier contract research organisation in Australia providing integrated preclinical services to the global pharmaceutical and biotechnology industries. For this reason TetraQ has been chosen to market NeuroSolutions' safety pharmacology services in Australasia. This includes the Qpatch, an automated electrophysiology device to screen drugs for potential adverse cardiac affects (commonly known as a hERG screening).

hERG screening is a crucial step in the process of discovering new medicines. The centrepiece of NeuroSolutions' leading edge electrophysiology and safety pharmacology services to the global drug discovery industry is a UK based hERG testing laboratory. Pharmaceutical and biotech companies are required to undertake a rigorous series of tests to evaluate any potential risks associated with their drugs. hERG testing was incorporated into international guidelines for new pharmaceuticals for human use after a number of important drugs were withdrawn from the US market following reports of heart malfunctions in patients who had been prescribed them.

"We are looking forward to working with TetraQ on marketing our hERG screening services in Australasia to expand the global reach of our profitable service business" said NeuroDiscovery's Chairman, Dr Mark Treherne.

TetraQ's Business Development Manger, Rosemarie Pennisi said becoming involved with NeuroSolutions' hERG testing program would complement the Queensland company's range of customised preclinical services and reputation for research excellence.

"The superior quality of the data generated by the QPatch -and the interpretation of the test results differentiates NeuroSolutions from other hERG testing providers. Both companies share a commitment to high standards and an understanding of the global market." Ms Pennisi said.

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options